Spots Global Cancer Trial Database for malignant peripheral nerve sheath tumors
Every month we try and update this database with for malignant peripheral nerve sheath tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | NCT00427583 | Malignant Perip... | imatinib mesyla... | 18 Years - | Novartis | |
| Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | NCT05245500 | Mesothelioma Non Small Cell ... Malignant Perip... Solid Tumor Pancreatic Aden... Advanced Solid ... | MRTX1719 | 18 Years - | Mirati Therapeutics Inc. | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | NCT05985161 | Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor | Selinexor | 12 Months - | Memorial Sloan Kettering Cancer Center | |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | NCT00427583 | Malignant Perip... | imatinib mesyla... | 18 Years - | Novartis | |
| Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | NCT03141021 | Malignant Perip... | - | Washington University School of Medicine | ||
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | NCT05985161 | Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor | Selinexor | 12 Months - | Memorial Sloan Kettering Cancer Center | |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | NCT03433183 | Malignant Perip... Neurofibromatos... | Selumetinib Sirolimus | 12 Years - | Sarcoma Alliance for Research through Collaboration | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | NCT03880123 | Liposarcoma Malignant Perip... Alveolar Soft P... Ewing Sarcoma Sarcoma | Selinexor Ixazomib | 14 Years - | Columbia University | |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | NCT06277154 | Leiomyosarcoma Liposarcoma Synovial Sarcom... Angiosarcoma Undifferentiate... Epithelioid Sar... Malignant Perip... Fibrosarcoma Pleomorphic Rha... Endometrial Str... Desmoplastic Sm... | MASCT-I Doxorubicin Ifosfamide | 18 Years - 70 Years | HRYZ Biotech Co. | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors | NCT02584647 | Sarcoma Malignant Perip... | PLX3397 Sirolimus | 18 Years - | Columbia University | |
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | NCT02008877 | Malignant Perip... Sarcoma | ganetespib Sirolimus | 16 Years - | Sarcoma Alliance for Research through Collaboration | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | NCT01169584 | Neuroblastoma Rhabdomyosarcom... Lymphoma Wilm's Tumor Ewing's Sarcoma | Recombinant Vac... | 2 Years - 21 Years | SillaJen, Inc. | |
| Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | NCT01169584 | Neuroblastoma Rhabdomyosarcom... Lymphoma Wilm's Tumor Ewing's Sarcoma | Recombinant Vac... | 2 Years - 21 Years | SillaJen, Inc. | |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | NCT04897321 | Pediatric Solid... Osteosarcoma Rhabdomyosarcom... Neuroblastoma Ewing Sarcoma Wilms Tumor Adrenocortical ... Desmoplastic Sm... Germ Cell Cance... Rhabdoid Tumor Clear Cell Sarc... Hepatoblastoma Melanoma Carcinoma Malignant Perip... Soft Tissue Sar... | Fludarabine Cyclophosphamid... MESNA B7-H3 CAR T cel... | - 21 Years | St. Jude Children's Research Hospital | |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT03618381 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma | second generati... second generati... | 1 Year - 30 Years | Seattle Children's Hospital | |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | NCT01661283 | Malignant Perip... MPNST Sarcoma | everolimus bevacizumab | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | NCT01661283 | Malignant Perip... MPNST Sarcoma | everolimus bevacizumab | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | NCT03433183 | Malignant Perip... Neurofibromatos... | Selumetinib Sirolimus | 12 Years - | Sarcoma Alliance for Research through Collaboration | |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | NCT03651375 | Sarcoma Fibrosarcoma Leiomyosarcoma Liposarcoma Myosarcoma Histiocytic Sar... Synovial Sarcom... Lymphangiosarco... Malignant Perip... Myxofibrosarcom... Myxoid Liposarc... Undifferentiate... Pleomorphic Lip... Undifferentiate... Dedifferentiate... Pleomorphic Rha... Malignant Trito... | Sequential chem... Hypofractionate... | 18 Years - 100 Years | Maria Sklodowska-Curie National Research Institute of Oncology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
